PQ/2961/2025 - SORAFENIB 200MG TAB

This tender, identified by reference PQ/2961/2025, is for the procurement of Sorafenib 200mg tablets. Sorafenib is a targeted therapy drug, specifically a tyrosine kinase inhibitor, used primarily in the treatment of certain types of cancer. It is commonly prescribed for advanced renal cell carcinoma (kidney cancer) and unresectable hepatocellular carcinoma (liver cancer). The '200MG TAB' indicates the dosage strength and form of the medication. This procurement is essential for healthcare providers, likely hospitals or pharmacies, to ensure the availability of this critical medication for cancer patients. The tender will specify the required quantities, packaging details, delivery timelines, and potentially the required pharmaceutical certifications and quality standards. The procurement process aims to secure a reliable supply of Sorafenib at competitive prices, adhering to all regulatory requirements for pharmaceutical products. The reference year '2025' suggests the period for which this supply is being contracted. Ensuring access to such specialized oncology drugs is vital for patient treatment and management of these serious diseases.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 3,360.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.